论文部分内容阅读
ＬｅｕｋｏＳｉｔｅ和 Ｉｌｅｘ Ｏｎｃｏｌｏｇｙ公司开发的 ｃａｍｐａｔｈ－１Ｈ（商品名Ｃａｍｐａｔｈ），经对９３例使用氟达拉滨（ｆｕｌｄａｒａｂｉｎｅ）治疗而难以治愈的慢性淋巴细胞性白血病患者进行的多国Ⅱ期临床研究表明，这一人源化淋巴细胞单克隆抗体有望用于
A Phase II multi-country clinical trial of Campath-1H (product name Campath) developed by LeukoSite and Ilex Oncology conducted in 93 patients with chronic lymphocytic leukemia refractory to fuldarabine treatment showed that this individual Monoclonal antibodies derived from lymphocytes are expected to be used